

Testosterone treatment does not cut fracture incidence in men with hypogonadism

January 18 2024, by Elana Gotkine



Testosterone treatment does not result in a lower incidence of clinical fractures among middle-aged and older men with hypogonadism, according to a study published in the Jan. 18 issue of the *New England*

Journal of Medicine.

Peter J. Snyder, M.D., from the Perelman School of Medicine at the University of Pennsylvania in Philadelphia, and colleagues examined the risk for clinical fracture in a time-to-event analysis subtrial of a randomized placebo-controlled trial that evaluated the cardiovascular safety of [testosterone treatment](#) in middle-aged and [older men](#) with hypogonadism. Eligible men were aged 45 to 80 years with preexisting, or a high risk for, [cardiovascular disease](#); one or more symptoms of hypogonadism; and two morning testosterone concentrations

Citation: Testosterone treatment does not cut fracture incidence in men with hypogonadism (2024, January 18) retrieved 29 April 2024 from <https://medicalxpress.com/news/2024-01-testosterone-treatment-fracture-incidence-men.html>

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.